SCYX
HEALTHCAREScynexis Inc
$0.98+0.04 (+4.14%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SCYX Today?
No stock-specific AI insight has been generated for SCYX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.57$1.31
$0.98
Fundamentals
Market Cap$78M
P/E Ratio—
EPS$-0.17
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-0.4%
Debt / Equity—
Trading
Volume388K
Avg Volume (10D)—
Shares Outstanding79.4M
SCYX News
20 articles- SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·May 7, 2026
- SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney DiseaseYahoo Finance·Mar 31, 2026
- SCYNEXIS Announces $40.0 Million Private PlacementYahoo Finance·Mar 31, 2026
- SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)Benzinga·Mar 31, 2026
- SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal TherapyYahoo Finance·Mar 12, 2026
- Scynexis: Q4 Earnings SnapshotYahoo Finance·Mar 4, 2026
- SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 4, 2026
- SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247Yahoo Finance·Feb 26, 2026
- CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of DirectorsYahoo Finance·Feb 17, 2026
- SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)Yahoo Finance·Jan 28, 2026
- SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247Yahoo Finance·Jan 21, 2026
- SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RequirementYahoo Finance·Dec 22, 2025
- SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSKYahoo Finance·Nov 19, 2025
- Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal InfectionsYahoo Finance·Nov 17, 2025
- Here's Why We're A Bit Worried About SCYNEXIS' (NASDAQ:SCYX) Cash Burn SituationYahoo Finance·Nov 10, 2025
- Scynexis: Q3 Earnings SnapshotYahoo Finance·Nov 5, 2025
- SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 5, 2025
- SCYNEXIS Reports Positive Phase 1 Results for Second-Generation Antifungal SCY-247Yahoo Finance·Oct 24, 2025
- SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO StudyYahoo Finance·Oct 15, 2025
- SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)Yahoo Finance·Sep 30, 2025
All 20 articles loaded
Price Data
Open$0.98
Previous Close$0.94
Day High$1.00
Day Low$0.93
52 Week High$1.31
52 Week Low$0.57
52-Week Range
$0.57$1.31
$0.98
Fundamentals
Market Cap$78M
P/E Ratio—
EPS$-0.17
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-0.4%
Debt / Equity—
Trading
Volume388K
Avg Volume (10D)—
Shares Outstanding79.4M
About Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, offers therapies for the treatment of yeast infections in the United States. The company is headquartered in Jersey City, New Jersey.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—